Expression of a novel apoptosis inhibitor-survivin in colorectal carcinoma

Table 1 Relationship between survivin PU and pathological parameter in 48 cases with colorectal carcinoma (mean±SD)

Subjects	Clinical pathological index	n	Survivin PU	P
Gender	Male	26	42.95 ± 16.87	P > 0.05
	Female	22	30.96 ± 16.06
Age (yr)	< 55	14	36.95 ± 19.86	P > 0.05
	55	34	38.96 ± 15.37
Tumor	< 3 cm	14	36.15 ± 16.29	P > 0.05
Diameter	3 cm	34	38.28 ± 18.16
Pathological	High and intermedium	24	33.16 ± 14.28	P < 0.05
	differentiated
Grade	Cannular adenocarcinoma
	Low differentiated tubular	10	51.93 ± 20.89
	adenocarcinoma
	Other types	14	35.61 ± 17.22
Lymph node	Negative	26	30.12 ± 13.33	P < 0.05
	Positive	22	56.21 ± 11.95
Dukes stage	A	16	20.16 ± 5.16	P < 0.05
	B	4	24.85 ± 3.12	A/B Stage
	C	10	45.13 ± 10.21	VS
	D	14	59.66 ± 10.21	C/D stage

Table 2 The comparison of survivin PU and AI in cancerous, paracancerous and normal tissues (mean±SD)

Subjects	Cancerous	Paracancerous	Normal	P
	tissues	tissues	tissues
Survivin PU	38.76 ± 5.14	25.17 ± 7.26a	0.57 ± 0.03a	P
AI (%)	4.65 ± 1.76	7.51 ± 2.63	1.75 ± 0.49	P

^aP<0.05, Survivin PU of cancerous tissue vs paracancerous or normal tissue; P = 0.0075, AI of paracancerous tissue vs cancerous tissue.